Specialty: Musculoskeletal disorders, Primary sub-specialty: Metabolic Bone Disease Musculoskeletal Diseases Metabolic Bone Disease
Conditions
Interventions
Participants with high risk of fracture were identified by their practice. They were sent a letter to invite them to take part in the study. Those accepting were randomised to group clinic or usual ca
Sponsors
North Tyneside General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients identified as high risk of an osteoporotic fracture, needing treatment 2. Patients aged 50 years and over 3. Patients giving informed consent to the study
Exclusion criteria
Exclusion criteria: 1. Patients not eligible for first line treatment as defined by North of Tyne Osteoporosis Guidance (encompassing FRAX calculation and NOGG guideline) 2. Patients not wishing to participate in the study 3. Patients unable to consent to participate in the study 4. Patient contraindications to bisphosphonates (upper gastrointestinal problems, severe impairment GFR<35ml/min, previous intolerance) 5. Terminally ill patients 6. Housebound patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean possession ratio (MPR) of bisphosphonates is measured using practice prescription records at 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Persistence with treatment is the time (in months) before the drug is no longer requested measured using practice prescription records by month up to 12 months 2. Patient satisfaction with group clinics, enabling factors and active ingredients were explored with qualitative interviews of osteoporosis group clinic participants and comparison with an established, but co-designed and therefore evolving inflammatory arthritis group clinic model 3. Cost analysis of the intervention was restricted to staff costs of, as assumptions of other costs being equivalent were met | — |
Countries
United Kingdom
Contacts
Public ContactNorma Cardill
Outcome results
None listed